Information Provided By: 
Fly News Breaks for September 30, 2015
SRPT, BMRN
Sep 30, 2015 | 09:13 EDT
Leerink analyst Joseph Schwartz reiterates an Outperform rating on BioMarin (BMRN) after meeting with the company's CEO J.J. Bienaime and CFO Dan Spiegelman. The orphan drug pricing landscape remains unchanged despite recent negative headlines, Schwartz tells investors in a research note. The "surprise" patent trial and appeal board decision in favor of BioMarin over Sarepta (SRPT) removes an overhang and highlights management's continued execution, the analyst adds.
News For BMRN;SRPT From the Last 2 Days
There are no results for your query BMRN;SRPT
